Improved Cognition in Alzheimer’s Disease With Short-Term D-Cycloserine Treatment
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glutamatergic neurotransmission is important for memory and cognition and is severely affected in Alzheimer's disease. D-Cycloserine exhibits partial agonist activity at the glycine site of N-methyl-D-aspartate subtype glutamate receptor, facilitating activation of the receptor and improving cognition and memory. METHOD: Seventeen patients with Alzheimer's disease received a three-phase, double-blind, placebo-controlled trial of 50 mg and 100 mg/day of D-cycloserine. RESULTS: D-Cycloserine was associated with significant improvement in scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale (improvement of 3.0 points) when given at a dose of 100 mg/day. CONCLUSIONS: D-Cycloserine has cognitive benefits for patients with Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
. Cerebral blood flow in dementia.
Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W. R., & Symon, L. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510088009 · Cited by 3,186
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Cited by
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
“11,12 We recently found that extinction of conditioned fear in rats was facilitated by DCS given in a 1-time dose prior to extinction training, which consists of exposure to a fearful stimulus in the absence of the aversive stimulus.”
BackgroundWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Microbiota-Brain-Gut Axis and Neurodegenerative Diseases
Quigley, E. M. M. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0802-6 · Cited by 804
Glutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Antibiotics, gut microbiota, and Alzheimer’s disease
Angelucci, F., Cechova, K., Amlerova, J., & Hort, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1494-4 · Cited by 454
“D-Cycloserin, which is also a NMDA receptor partial agonist, improves cognitive deficits in aged rats [101] and in AD patients [102].”
BackgroundResultNMDA receptors in clinical neurology: excitatory times ahead
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70165-0 · Cited by 415
Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine
Nitsche, M. A., Jaussi, W., Liebetanz, D., Lang, N., Tergau, F., & Paulus, W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300517 · Cited by 385
“Indeed, in some studies, it has been shown to improve cognitive functions in Alzheimer and schizophrenic patients, if administered in a proper dosage (Goff et al, 1995, 1999; Tsai et al, 1998, 1999), although the results achieved so far are mixed (Laake and Oeksengaard, 2002).”
BackgroundResultMiklossy, J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-90 · Cited by 355
Wistar rats show episodic-like memory for unique experiences
KARTTEKE, E., DESOUZASILVA, M., HUSTON, J., & DERE, E. (2006) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2005.10.002 · Cited by 250
Effect of nutrition on neurodegenerative diseases. A systematic review
Bianchi, V. E., Herrera, P. F., & Laura, R. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1681088 · Cited by 249
“microbiota in AD patients the cognition improved [239,240] and oxidative stress in the brain decreased significantly activating SIRT-1 pathway [241].”
BackgroundD-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8480 · Cited by 200
“2004), social phobia (Hofmann et al., 2006), implicit memory (Schwartz et al., 1996), and subscales of dementia in Alzheimer’s disease (Tsai et al., 1999).”
BackgroundCombination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
Time to test antibacterial therapy in Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Watling, M., & Imbimbo, B. P. (2019) · Brain · doi:10.1093/brain/awz244 · Cited by 161
D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review
Schade, S., & Paulus, W. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv102 · Cited by 135
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis
Rodrigues, H., Figueira, I., Lopes, A., Gonçalves, R., Mendlowicz, M. V., Coutinho, E. S. F., & Ventura, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093519 · Cited by 109
“Originally designed to be a tuberculostatic agent, DCS was later used as a potential treatment for Alzheimer’s dementia and negative symptoms in schizophrenia [18;19].”
MethodSchoenmaker, N., & Van Gool, W. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00884-1 · Cited by 86
Otto, M. W., Basden, S. L., Leyro, T. M., McHugh, R. K., & Hofmann, S. G. (2007) · CNS Spectrums · doi:10.1017/s1092852900020526 · Cited by 53
Pharmacological enhancement of memory or cognition in normal subjects
Lynch, G. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00090 · Cited by 46
“…has been known for some time that the site is important for induction of LTP (Oliver et al., 1990) and, as expected from this, D-cycloserine enhances various forms of memory in animals (Flood et al., 1992; Baxter et al., 1994; Tsai et al., 1999; Normann and Berger, 2008; Peters and De Vries, 2013).”
BackgroundCatumbela, C. S. G., Giridharan, V. V., Barichello, T., & Morales, R. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00369-7 · Cited by 37
“In support of these findings, Tsai and colleagues showed that AD patients displayed significant improvement in ADAS-Cog scores upon daily administration of cycloserine during a 4-week, double-blind, placebo-controlled study [21].”
ResultEffects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo
Hopkins, S. C., Campbell, U. C., Heffernan, M. L. R., Spear, K. L., Jeggo, R. D., Spanswick, D. C., Varney, M. A., & Large, T. H. (2013) · Pharmacology Research & Perspectives · doi:10.1002/prp2.7 · Cited by 34
Liu, Z., Wei, S., Chen, X., Liu, L., Wei, Z., Liao, Z., Wu, J., Li, Z., Zhou, H., & Wang, D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.833365 · Cited by 10
“Similarly, in 1999, d-cycloserine was found to effectively improve cognitive impairment in patients with AD (Tsai et al., 1999), but these positive effects were not found in subsequent cochrane review (Laake and Oeksengaard, 2002).”
Background
Metadata
- Authors
- Tsai, G. E., Falk, W. E., Gunther, J., & Coyle, J. T.
- Venue
- American Journal of Psychiatry
- Published
- 1999-03-01
- Volume
- 156
- Issue
- 3
- Pages
- 467-469
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1959246743
- Cited by
- 128
- References
- 2
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.